Management of Patients on Hydrochlorothiazide and Lisinopril Combination Therapy

Introduction to Monitoring

• Regular blood pressure monitoring is recommended, with weekly home monitoring for the first month for patients with pre-existing hypertension, and clinic monitoring at 3 months after initiation and then every 6 months, as suggested by guidelines from various societies, although a specific relevant guideline is not directly cited, general monitoring frameworks can be applied 1

Renal Function Monitoring

• Monitor for changes in creatinine and eGFR, considering that small increases in creatinine (up to 30%) are expected and acceptable with ACE inhibitors, as recommended by the American College of Cardiology, with the goal of maintaining optimal heart failure management 2, 3
• A >30% increase (NICE guideline) or >50% increase (ESC/SIGN guidelines) from baseline in creatinine levels is a threshold for concern, and if exceeded, consider reducing the dose or reviewing other nephrotoxic medications, to minimize the risk of adverse effects and optimize renal function 4

Electrolyte Monitoring

• Potassium levels are critical to monitor due to the opposing effects of lisinopril and HCTZ, with lisinopril tending to increase potassium levels and HCTZ tending to decrease them, requiring vigilant monitoring, and considering reducing lisinopril dose by 50% if potassium reaches 5.5-5.9 mmol/L and temporarily discontinuing lisinopril if potassium reaches ≥6.0 mmol/L, as recommended by the British Journal of Pharmacology guideline 4

General Management

• Avoid NSAIDs as they can worsen both heart failure and renal function, and educate patients about avoiding over-the-counter NSAIDs, as advised by the American College of Cardiology 2
• Monitor for signs of dehydration or volume depletion, orthostatic hypotension, electrolyte imbalances, and worsening renal function, as part of comprehensive care, with a recommended monitoring schedule that includes:

5, 6, 4

• The American College of Cardiology recommends using ACE inhibitors or ARBs in all patients with CHF and CKD stage 3, with ACE inhibitors being strongly recommended for patients with LVEF ≤40% to prevent symptomatic HF and reduce mortality, and ARBs being used if ACE inhibitors are not tolerated 7
• Statin or statin/ezetimibe combination is strongly recommended for adults ≥50 years with CKD stage 3, and for adults 18-49 years with CKD, statin treatment is suggested if they have known coronary disease, diabetes mellitus, prior ischemic stroke, or estimated 10-year incidence of coronary death or MI >10% 8
• Low-dose aspirin is recommended for secondary prevention in patients with established ischemic cardiovascular disease, and P2Y12 inhibitors should be considered when there is aspirin intolerance 8
• Beta-blockers are recommended in all patients with CHF and CKD stage 3, with metoprolol succinate being a preferred option, starting at 25 mg daily for NYHA Class II or 12.5 mg daily for more severe heart failure, and doubling the dose every two weeks to the highest tolerated level or up to 200 mg, while monitoring for symptomatic bradycardia and adjusting the dose accordingly 7
• Loop diuretics remain effective even with impaired renal function, unlike thiazide diuretics which lose effectiveness when creatinine clearance falls below 40 ml/min, as stated by the European Heart Journal and American College of Cardiology 9, 3
• Adjust furosemide dose by reducing it by 25-50% if signs of fluid overload persist, or consider temporary interruption if euvolemic or showing signs of dehydration, to optimize diuretic therapy and minimize adverse effects 6
• Premature discontinuation of heart failure medications, including ACE inhibitors/ARBs and diuretics, should be avoided, as small increases in creatinine are expected and not necessarily harmful 2, 6, 3